The Gonorrhea Diagnostics Market is estimated to reach $13.6 billion by 2028, growing at a CAGR of 8.9% over the forecast period 2023-2028. Currently, several U.S. government agencies are supporting the global market for gonorrhea treatments to a greater extent. According to CDC, the U.S. government released the 5-year national action plan to Combat Antibiotic-resistant Bacteria (CARB), which would work toward the prevention, detection and control of antibiotic resistance by implementing new molecular diagnostics techniques. To support the research on this antimicrobial resistance, CARB provides funding to nine regional public health laboratories. Four of these nine sites would concentrate on testing and genome sequencing for gonorrhea as it poses a serious danger to the nation's health. These institutions would use approved molecular diagnostics assays to determine the presence or absence of any antibiotic-resistant strains, which would then assist in giving patients the right care. These elements are driving the growth of the Gonorrhea Diagnostics industry.

For More Queries About "Gonorrhea Diagnostics Market" @

Gonorrhea Diagnostics Market Drivers:

  • High-risk Complications Associated with Gonorrhea:

Neisseria gonorrhoeae, a bacterium, is the cause of the STD gonorrhea, which is quite widespread. This illness causes high morbidity and fatality rates. If left untreated, the infection can spread to the upper reproductive system and result in pelvic inflammatory disease (PID), ectopic pregnancy, persistent discomfort and infertility. Owing to the asymptomatic nature of the lower vaginal tract gonorrhea infection, one in five untreated women could develop PID. Ciprofloxacin and fluoroquinolones were suggested as gonorrhea treatments. Cephalosporins, ceftriaxone or cefixime are the recommended alternatives. However, cephalosporins, including cefuroxime, are currently being used to treat gonorrhea. According to a report by the National Library of Medicine (NLM), gonorrhea during pregnancy causes chorioamnionitis, which is worsened by septic abortion in 13% of cases, premature or early biological membrane rupture in 29% of cases and preterm delivery in 23% of cases. Owing to the high prevalence of gonorrhea-related problems, patients are encouraged to seek treatment as soon as possible.

  • Nucleic Acid Amplification Tests (NAATs) are One of the Novel Diagnostic Procedures that have Emerged in Response to the Rising Frequency of Gonorrhea.

A rise in the prevalence of gonorrhea has prompted the development of new diagnostic procedures, such as Nucleic Acid Amplification Tests (NAATs), which allow for early detection to prevent the infection from spreading to the upper genital tract. The diagnostic screening is an essential first step since gonorrhea, particularly in women, is usually asymptomatic and can spread to the upper genital tract. Nucleic Acid Amplification Tests (NAATs) are recommended for the diagnosis of chlamydia and gonorrhea owing to their high sensitivity and specificity, but a variety of urogenital specimens are used for testing at the clinical level. According to a report by the National Library of Medicine (NLM), the specificity rates of NAATs are generally high, often exceeding 98%. However, the positive predictive values vary depending on the patient population. In particular, positive predictive values can be unacceptably low in populations in which the prevalence of Neisseria gonorrhoeae is low. A systematic review estimated that the overall performance of NAATs for gonorrhea was just 55.6% for urine samples compared with 94.2% for cervical samples, with a specificity of 98.7% and 99.2%, respectively. The Gonorrhea Diagnostics industry has grown due to the new diagnostic techniques that have emerged in response to the rising prevalence of gonorrhea.

R&D Investment:

In May 2022, Biomerieux acquired 100% ownership of Specific Diagnostics for an acquisition price equivalent to 3.2% of Biomerieux's market capitalization. The acquisition price has been paid with a combination of cash and shares issued to certain Specific Diagnostics shareholders. The Biomerieux expects to further develop its global leadership in clinical microbiology, bringing major innovation to the market and further strengthening its fight against Antimicrobial Resistance.

Major Players in Gonorrhea Diagnostics Market:

The major companies in the Gonorrhea Diagnostics Market include Abbott Laboratories, Bayer, Agilent Technologies, Biomerieux, Danaher, Thermo Fisher Scientific, F. Hoffmann-La Roche and others.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.